Biblio Discovery — Demo Discovery Service

18 hasil untuk "Bryan C. Fuchs"

Menampilkan 1–18 · 0,50 detik · RSS

  1. Artikel Jurnal

    New Directions in the Study and Treatment of Metastatic Cancer

    Byunghee Yoo; Bryan C. Fuchs; Zdravka Medarova

    Frontiers in Oncology, Vol. 8 · 2018 · Inggris · DOAJ Scopus

    Traditional cancer therapy has relied on a strictly cytotoxic approach that views non-metastatic and metastatic tumor cells as identical in terms of molecular biology and sensitivity to therapeutic intervention. Mounting evidence suggests that, in fact, non-metastatic and metastatic tumor cells…

  2. Artikel Jurnal

    The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

    Derek J. Erstad; Andrew M. Tager; Yujin Hoshida dkk.

    Molecular & Cellular Oncology, Vol. 4 No. 3 · 2017 · Inggris · DOAJ Scopus

    Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals…

  3. Artikel Jurnal

    Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis

    Byeong-Moo Kim; Ahmed Maher Abdelfattah; Robin Vasan dkk.

    Scientific Reports, Vol. 8 No. 1 · 2018 · Inggris · DOAJ Scopus

    Abstract Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of disease severity, starting from pure steatosis, leading to fatty inflammation labeled as non-alcoholic steatohepatitis (NASH), and finally fibrosis leading to cirrhosis. Activated hepatic stellate cells (HSCs) are…

  4. Artikel Jurnal Teks lengkap

    Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection

    Romeo Papazyan; Nicky Ferdyan; Karthik Srinivasan dkk.

    Microorganisms, Vol. 11 No. 1 · 2023 · Inggris · DOAJ Scopus

    Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce recurrent Clostridioides difficile infection (rCDI), with proposed mechanisms including restoration of the microbiota and microbiota-mediated functions, such as bile acid (BA) metabolism. This study reports a…

  5. Artikel Jurnal

    Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance

    Jennifer L. Green; Robin E. Osterhout; Amy L. Klova dkk.

    Molecular Therapy: Oncolytics, Vol. 23 · 2021 · Inggris · DOAJ

    Although anti-tumor activities of type I interferons (IFNs) have been recognized for decades, the molecular mechanisms contributing to clinical response remain poorly understood. The complex functions of these pleiotropic cytokines include stimulation of innate and adaptive immune responses against…

  6. Artikel Jurnal

    Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy

    Derek J. Erstad; Mozhdeh Sojoodi; Martin S. Taylor dkk.

    Disease Models & Mechanisms, Vol. 11 No. 7 · 2018 · Inggris · DOAJ Scopus

    Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic…

  7. Artikel Jurnal

    An angiotensin system inhibitor (losartan) potentiates antitumor efficacy of cisplatin in a murine model of non–small cell lung cancerCentral MessagePerspective

    Hexiao Tang, MD, PhD; Eric Abston, MD, PhD; Mozhdeh Sojoodi, PhD dkk.

    JTCVS Open, Vol. 18 · 2024 · Inggris · DOAJ Scopus

    Objective: Previous studies have demonstrated synergistic antitumor effects of angiotensin system inhibition (ASI) combined with cisplatin therapy in pancreatic cancer. This study examines whether or not synergistic antitumor effects occur with combination ASI and cisplatin treatment in lung…

  8. Artikel Jurnal

    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation

    Jamie Bates; Archana Vijayakumar; Sarani Ghoshal dkk.

    Journal of Hepatology · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a chronic liver disease characterized by hepatic lipid accumulation, inflammation, and progressive fibrosis. Acetyl-CoA carboxylase (ACC) catalyzes the rate-limiting step of de novo lipogenesis and regulates fatty acid β-oxidation in…

  9. Artikel Jurnal Teks lengkap

    Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis

    Lindsay Y. King; Kara B. Johnson; Hui Zheng dkk.

    PLoS ONE, Vol. 9 No. 12 · 2014 · Inggris · PLOS Scopus

    Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma…

    Juga tersedia di: DOAJ

  10. Artikel Jurnal

    Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

    Gong Zhang; Yufeng Wang; Bryan C. Fuchs dkk.

    Frontiers in Oncology, Vol. 12 · 2022 · Inggris · DOAJ Scopus

    BackgroundSorafenib, a kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC) but provides only a limited survival benefit. Disulfiram (DSF), a drug for treating alcoholism and a chelator of copper (Cu), forms a complex with Cu (DSF/Cu). DSF/Cu is a potent inducer of…

  11. Artikel Jurnal

    Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis

    Philip A. Waghorn; Diego S. Ferreira; Derek J. Erstad dkk.

    Scientific Reports, Vol. 11 No. 1 · 2021 · Inggris · DOAJ Scopus

    Abstract Non-alcoholic steatohepatitis (NASH) is an increasing cause of chronic liver disease characterized by steatosis, inflammation, and fibrosis which can lead to cirrhosis, hepatocellular carcinoma, and mortality. Quantitative, noninvasive methods for characterizing the pathophysiology of NASH…

  12. Artikel Jurnal

    Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrolysis Function and Promotes Collagen Resolution in LiverSummary

    Mozhdeh Sojoodi; Derek J. Erstad; Stephen C. Barrett dkk.

    Cellular and Molecular Gastroenterology and Hepatology, Vol. 13 No. 5 · 2022 · Inggris · DOAJ Scopus

    Background & Aims: During liver fibrosis, tissue repair mechanisms replace necrotic tissue with highly stabilized extracellular matrix proteins. Extracellular matrix stabilization influences the speed of tissue recovery. Here, we studied the expression and function of peroxidasin (PXDN), a…

  13. Artikel Jurnal

    Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

    Derek J. Erstad; Christian T. Farrar; Sarani Ghoshal dkk.

    Hepatology Communications, Vol. 2 No. 7 · 2018 · Inggris · DOAJ Scopus

    We examined a novel farnesoid X receptor agonist, EDP‐305, for its antifibrotic effect in bile duct ligation (BDL) and choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) models of hepatic injury. We used molecular magnetic resonance imaging with the type 1 collagen‐binding probe…

  14. Artikel Jurnal

    Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation

    Emilie Crouchet; Shen Li; Mozhdeh Sojoodi dkk.

    JCI Insight, Vol. 7 No. 13 · 2022 · Inggris · DOAJ Scopus

    Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients, for which chemopreventive strategies are lacking. Recently, we developed a simple human cell-based system modeling a clinical prognostic liver signature (PLS) predicting liver disease progression and HCC risk. In a…

  15. Artikel Jurnal

    A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery

    Emilie Crouchet; Simonetta Bandiera; Naoto Fujiwara dkk.

    Nature Communications, Vol. 12 No. 1 · 2021 · Inggris · DOAJ Scopus

    Drug and target discovery for advanced liver disease are hampered by a lack of suitable models for clinical translation. Here the authors present a human liver cell-based system modeling a clinical prognostic signature allowing to propose nizatidine for treatment of advanced liver fibrosis and…